Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An illness severity score for multiple sclerosis.

M R Mickey, G W Ellison, L W Myers

    Neurology
    |October 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Clinical evaluation of a pre-tied ligating loop for liver biopsy and liver lobectomy.

    The Journal of small animal practice·2013
    Same author

    SEROTYPING FOR HOMOTRANSPLANTATION. VII. SELECTION OF KIDNEY DONORS FOR THIRTY-TWO RECIPIENTS.

    Annals of the New York Academy of Sciences·2010
    Same author

    Pericardial lipoma in a geriatric dog with an incidentally discovered thoracic mass.

    The Journal of small animal practice·2007
    Same author

    Cerebrospinal fluid immunoglobulin G promotes oligodendrocyte progenitor cell migration.

    Journal of neuroscience research·2004
    Same author

    Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2003
    Same author

    Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995.

    Neurology·2002
    Same journal

    Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

    Neurology·2026
    Same journal

    Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

    Neurology·2026
    Same journal

    Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

    Neurology·2026
    Same journal

    Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.

    Neurology·2026
    Same journal

    Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

    Neurology·2026
    Same journal

    At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

    Neurology·2026
    See all related articles

    A new Illness Severity Score (ISS) was developed to better evaluate Multiple Sclerosis (MS) progression in clinical trials. This validated score offers a more sensitive measure of disability and disease severity.

    Area of Science:

    • Neurology
    • Clinical Trials
    • Biostatistics

    Background:

    • Evaluating disease progression in Multiple Sclerosis (MS) clinical trials requires a sensitive scoring system.
    • Current methods may not fully capture the relative severity of disability.

    Purpose of the Study:

    • To develop a novel scoring system, the Illness Severity Score (ISS), for enhanced evaluation of MS progression.
    • To create a more sensitive measure reflecting clinical assessment of disability severity.

    Main Methods:

    • Developed the Illness Severity Score (ISS) by summing weighted ratings from the Kurtzke Disability Status Scale, Functional Systems Scales, and illness phase.
    • Calculated weights through clinical pairwise patient comparisons.
    • Standardized the score to a mean of 50 and standard deviation of 10 in a patient cohort.

    Related Experiment Videos

  • Assessed score reproducibility via independent scorings (correlation = 0.93).

    • Main Results:

    • The Illness Severity Score (ISS) demonstrated high reproducibility (correlation = 0.93).
    • The ISS proved satisfactory for primary assessment in a small-scale clinical trial setting.
    • The score provides a sensitive measure of disability and disease severity.

    Conclusions:

    • The developed Illness Severity Score (ISS) is a reproducible and sensitive tool for assessing MS progression.
    • The ISS is suitable for use as a primary outcome measure in MS clinical trials.
    • This scoring system enhances the evaluation of therapeutic effects in MS.